Cargando…

A novel autoantibody signatures for enhanced clinical diagnosis of pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease that requires precise diagnosis for effective treatment. However, the diagnostic value of carbohydrate antigen 19 − 9 (CA19-9) is limited. Therefore, this study aims to identify novel tumor-associated autoantibodies (TAAbs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tiandong, Xia, Junfen, Yun, Huan, Sun, Guiying, Shen, Yajing, Wang, Peng, Shi, Jianxiang, Wang, Keyan, Yang, Hongwei, Ye, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655307/ https://www.ncbi.nlm.nih.gov/pubmed/37974212 http://dx.doi.org/10.1186/s12935-023-03107-1

Ejemplares similares

Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer
por: Qiu, Cuipeng, et al.
Publicado: (2021)

A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody‐antigen system
por: Wu, Jinyu, et al.
Publicado: (2021)

Human Proteome Microarray identifies autoantibodies to tumor‐associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma
por: Yang, Qian, et al.
Publicado: (2023)

Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Shen, Quan, et al.
Publicado: (2018)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021)

Polymorphisms of nucleotide excision repair genes associated with colorectal cancer risk: Meta-analysis and trial sequential analysis
por: Yi, Chuncheng, et al.
Publicado: (2022)

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
por: Zhang, Deyu, et al.
Publicado: (2022)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Autoantibodies against tumor‐associated antigens combined with microRNAs in detecting esophageal squamous cell carcinoma
por: Sun, Guiying, et al.
Publicado: (2019)

Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Kim, Hongbeom, et al.
Publicado: (2020)

Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
por: Schnipper, Julie, et al.
Publicado: (2020)

Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma
por: Hu, Xi, et al.
Publicado: (2021)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA
por: Wu, Huanwen, et al.
Publicado: (2022)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma
por: Chen, Dung-Tsa, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
por: Ren, Min, et al.
Publicado: (2023)

Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma
por: Mascharak, Shamik, et al.
Publicado: (2023)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Advances in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma and Premalignant Pancreatic Lesions
por: Yamada, Reiko, et al.
Publicado: (2023)

Correction: Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Publicado: (2018)

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
por: Haider, Syed, et al.
Publicado: (2014)

Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma
por: Fang, Lishan, et al.
Publicado: (2023)

A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma
por: Li, Ang, et al.
Publicado: (2022)

Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma
por: Wu, Mengwei, et al.
Publicado: (2020)

Identification of novel tumor-associated antigens and evaluation of a panel of autoantibodies in detecting oral cancer
por: Xie, Weihong, et al.
Publicado: (2023)

Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples
por: Zhang, Xiaohan, et al.
Publicado: (2020)

Diagnosis of Pancreatic Ductal Adenocarcinoma by Immuno-Positron Emission Tomography
por: González-Gómez, Ruth, et al.
Publicado: (2021)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
por: Sturm, Niklas, et al.
Publicado: (2022)

Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma
por: Nakaoka, Kazunori, et al.
Publicado: (2023)

A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma
por: Zhou, Chenhao, et al.
Publicado: (2019)

Metabolism remodeling in pancreatic ductal adenocarcinoma
por: Li, Jin-Tao, et al.
Publicado: (2019)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma
por: Lu, Hao, et al.
Publicado: (2022)

Using protein microarray to identify and evaluate autoantibodies to tumor‐associated antigens in ovarian cancer
por: Ma, Yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pdmdu97dvbscrgu3veivgqf9ab